Compare Stocks: ZYBT, IKT, VNDA, and NMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$2.50 +4.6%	$2.16	$1.33 ▼ $2.54	$333.49M	0.95	518,910 shs	734,678 shs
NMRA Neumora Therapeutics	$1.53 -6.4%	$1.61	$0.83 ▼ $3.65	$306.27M	2.75	757,313 shs	1.16 million shs
VNDA Vanda Pharmaceuticals	$5.33 +0.9%	$5.60	$4.27 ▼ $9.94	$319.25M	0.64	1.03 million shs	774,242 shs
ZYBT Zhengye Biotechnology	$1.95 -4.4%	$1.36	$0.62 ▼ $13.08	$96.68M	-2.74	4.70 million shs	147,169 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	+4.60%	+4.60%	+7.30%	+47.06%	+249,999,900.00%
NMRA Neumora Therapeutics	-6.44%	+0.33%	+2.35%	-17.12%	-5.86%
VNDA Vanda Pharmaceuticals	+0.95%	+1.33%	+2.90%	-14.31%	+12.21%
ZYBT Zhengye Biotechnology	-4.41%	+28.29%	+12.72%	+126.77%	-72.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$2.50 +4.6%	$2.16	$1.33 ▼ $2.54	$333.49M	0.95	518,910 shs	734,678 shs
NMRA Neumora Therapeutics	$1.53 -6.4%	$1.61	$0.83 ▼ $3.65	$306.27M	2.75	757,313 shs	1.16 million shs
VNDA Vanda Pharmaceuticals	$5.33 +0.9%	$5.60	$4.27 ▼ $9.94	$319.25M	0.64	1.03 million shs	774,242 shs
ZYBT Zhengye Biotechnology	$1.95 -4.4%	$1.36	$0.62 ▼ $13.08	$96.68M	-2.74	4.70 million shs	147,169 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	+4.60%	+4.60%	+7.30%	+47.06%	+249,999,900.00%
NMRA Neumora Therapeutics	-6.44%	+0.33%	+2.35%	-17.12%	-5.86%
VNDA Vanda Pharmaceuticals	+0.95%	+1.33%	+2.90%	-14.31%	+12.21%
ZYBT Zhengye Biotechnology	-4.41%	+28.29%	+12.72%	+126.77%	-72.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	116.00% Upside
NMRA Neumora Therapeutics	2.60	Moderate Buy	$6.57	330.91% Upside
VNDA Vanda Pharmaceuticals	2.50	Moderate Buy	$13.70	157.04% Upside
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZYBT, IKT, VNDA, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00 ➝ $20.00
8/10/2026	VNDA Vanda Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $12.00
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/20/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/13/2026	NMRA Neumora Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $5.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKT Inhibikase Therapeutics	$260K	1,341.73	N/A	N/A	$2.30 per share	1.09
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
VNDA Vanda Pharmaceuticals	$215.72M	1.49	N/A	N/A	$5.54 per share	0.96
ZYBT Zhengye Biotechnology	$16.64M	5.55	N/A	N/A	$0.93 per share	2.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ZYBT, IKT, VNDA, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKT Inhibikase Therapeutics	N/A	15.82	15.82
NMRA Neumora Therapeutics	1.19	4.50	4.50
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60
ZYBT Zhengye Biotechnology	0.03	1.14	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKT Inhibikase Therapeutics	3.81%
NMRA Neumora Therapeutics	47.65%
VNDA Vanda Pharmaceuticals	88.14%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
IKT Inhibikase Therapeutics	7.10%
NMRA Neumora Therapeutics	26.94%
VNDA Vanda Pharmaceuticals	10.70%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKT Inhibikase Therapeutics	6	139.54 million	129.63 million	N/A
NMRA Neumora Therapeutics	108	187.90 million	137.28 million	Optionable
VNDA Vanda Pharmaceuticals	290	60.46 million	53.99 million	Optionable
ZYBT Zhengye Biotechnology	278	47.39 million	N/A	N/A

ZYBT, IKT, VNDA, and NMRA Headlines

Recent News About These Companies

Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance

August 6, 2026 | tipranks.com

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

August 5, 2026 | quiverquant.comQ

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter

February 10, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders

February 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT, IKT, VNDA, and NMRA Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

$2.50 +0.11 (+4.60%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$2.50 +0.00 (+0.20%)

As of 08/24/2026 07:22 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Neumora Therapeutics NASDAQ:NMRA

$1.52 -0.11 (-6.44%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$1.52 0.00 (0.00%)

As of 08/24/2026 05:17 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Vanda Pharmaceuticals NASDAQ:VNDA

$5.33 +0.05 (+0.95%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$5.25 -0.08 (-1.50%)

As of 08/24/2026 07:07 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Zhengye Biotechnology NASDAQ:ZYBT

$1.95 -0.09 (-4.41%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$1.94 -0.01 (-0.51%)

As of 08/24/2026 07:17 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYBT, IKT, VNDA, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYBT, IKT, VNDA, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYBT, IKT, VNDA, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT, IKT, VNDA, and NMRA Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

Neumora Therapeutics NASDAQ:NMRA

Vanda Pharmaceuticals NASDAQ:VNDA

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYBT, IKT, VNDA, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYBT, IKT, VNDA, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYBT, IKT, VNDA, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT, IKT, VNDA, and NMRA Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

Neumora Therapeutics NASDAQ:NMRA

Vanda Pharmaceuticals NASDAQ:VNDA

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools